Cytek Biosciences, Inc. (CTKB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 18, 2025, details the results of Cytek Biosciences, Inc.'s 2025 Annual Meeting of Stockholders. The meeting was held virtually on June 18, 2025. As of the record date (April 21, 2025), the company had 127,599,142 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Approximately 81.4% of outstanding shares (103,869,471 shares) were present or represented by proxy. The following matters were voted upon:
- Election of Class I Directors:
- Richard Chin, MD: Elected with 81,794,582 votes for and 208,499 votes withheld.
- Deborah Neff: Elected with 33,819,367 votes for and 48,183,714 votes withheld.
- Executive Compensation (Say-on-Pay): The non-binding advisory vote for executive compensation for the year ended December 31, 2024, was approved with 76,368,883 votes for and 5,630,057 votes against.
- Ratification of Auditors: The selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 95,862,612 votes for and 7,657,004 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting vote tallies.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director nominee Deborah Neff (48.2 million) compared to votes for (33.8 million), noting that she was still elected as the votes for exceeded the votes withheld.
- Confirm the high level of broker non-votes (21,866,390) on the director election and executive compensation proposals.
- Review the upcoming fiscal year 2025 audit engagement with Deloitte & Touche LLP as ratified by shareholders.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent from this 8-K.